Know Cancer

forgot password

PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2

18 Years
Not Enrolling
Polycystic Ovary Syndrome

Thank you

Trial Information

PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2

Polycystic Ovary Syndrome, or PCOS, is the most common endocrine disorder in women.
Depending on the strictness of the diagnostic criteria used, it is thought to occur in about
6-10% of all women, many of whom do not know they have the syndrome. Women with PCOS
produce abnormally high levels of male hormones (hyperandrogenism); this counteracts their
ovaries' ability to make enough of the female hormones estrogen and progesterone needed for
normal menstruation. PCOS is the number one cause of hormonally related infertility and
also increases women's risks for diabetes, high blood pressure, hypercholesteremia,
cardiovascular disease and certain cancers. It is currently unclear to what extent PCOS and
PCOS-associated traits (hyperandrogenism, hyperinsulinemia, insulin resistance, type 2
diabetes, dyslipidemia, hypertension, obesity, and coronary artery disease) are the results
of environmental factors or genetic predisposition. Therefore, the NIEHS Program in
Clinical Research is conducting a multi-phase twin study to measure the extent of PCOS
heritability and to identify environmental and genetic factors involved in the development
of PCOS. The proposal described here is for Phase 2 of this study. The goals of Phase 2
are to: 1) establish more reliable concordance rates and baseline heritability estimates for
PCOS in MZ and DZ twins; and 2) establish a cohort of intact MZ and DZ female twin pairs
with PCOS as a resource for future studies.

In Phase 1, about 1500 individual female twins were identified from the Mid-Atlantic Twin
Registry (MATR) based on self report of a history of irregular periods and/or cystic ovaries
in the MATR General Health Screening Questionnaire. Those twins were surveyed by phone for
other traits associated with PCOS. In Phase 2, the twins most likely to have PCOS based on
their answers to the Phase 1 phone survey will be recontacted for further PCOS screening.
One or both twins in a pair will be screened for elevated levels of testosterone (total and
free testosterone, bioavailable testosterone or BaT; free androgen index or FAI).
Hyperandrogenism is one of the hallmark traits of PCOS and can be exhibited either
biochemically (elevated testosterone) or clinically (hirsutism, acne, hair loss, alopecia,
other). If one twin in a pair has an elevated BaT level, then both twins in the pair will
be asked to undergo a medical evaluation for PCOS confirmation. This includes a physical
exam, medical history, ultrasound, 2-hour glucose tolerance and other biochemical blood
tests, and a Ferriman-Gallwey evaluation for abnormal hirsutism (another characteristic of
PCOS). The women will also be tested for pregnancy and zygosity. Their female co-twins
will be invited to undergo a similar medical evaluation.

Depending on their PCOS traits, twin pairs in which neither member has elevated testosterone
levels might be asked to undergo the medical evaluation as well. In clinical practice, PCOS
diagnoses are often made on women with normal testosterone levels if they have other certain
PCOS traits. The determination to include pairs in which both members have normal
testosterone levels will be made depending on their collective PCOS traits that they
reported on their Phase 1 survey.

Inclusion Criteria


To be included in this study, primary twins must:

1. Be a premenopausal female twin over the age 18 (this will be asked during

2. Have a living female co-twin (this will be asked during recruitment).

3. Have a history of probable PCOS defined by having one or more of the following
criteria as self-reported in the Phase 1 PCOS survey. These traits will be confirmed
during medical evaluation:

1. History of chronically irregular menstrual cycles

2. History of hirsutism

3. History of hair loss

4. Cysts in ovaries

5. Body-mass index greater than 25

6. Acne

4. Be able and willing to give informed consent.

5. Agree to undergo a medical evaluation for PCOS.

To be included in this study, co-twins must:

1. Be a premenopausal female twin over the age of 18 (this will be asked during

2. Be able and willing to give informed consent.

3. Agree to undergo a medical evaluation for PCOS.


Women will be excluded from the study if they are pregnant or have given birth within the
past six months.

Women will also be excluded if they are currently menopausal or past menopause.

Women with any condition that, in the opinion of the investigators, could affect the
validity of the study results will be excluded from participating.

Subjects will not be excluded based on race, ethnicity or religion.

Type of Study:


Study Design:



United States: Federal Government

Study ID:




Start Date:

February 2007

Completion Date:

March 2010

Related Keywords:

  • Polycystic Ovary Syndrome
  • Cystic Ovaries
  • Hyperandrogenism
  • Anovulation
  • Concordance Rates
  • Baseline Heritability
  • Polycystic Ovary Syndrome
  • POS
  • Polycystic Ovary Syndrome



Duke University Medical CenterDurham, North Carolina  27710